Influential pricing watchdog ICER - the Institute for Clinical and Economic Review - has released a final report into the cost-effectiveness of Eli Lilly’s GLP- 15 February 2022
Danish diabetes giant Novo Nordisk has reported net sales of 140 billion kroner ($21.3 billion) in 2021, an 11% increase from the year before. 2 February 2022
Novo Seeds, the early stage investment and company creation team of Novo Nordisk’s primary shareholder, has published a review of its activities in 2021. 12 January 2022
Boston, USA-based cost-effectiveness watchdog The Institute for Clinical and Economic Review (ICER) has posted a revised “Evidence Report” for Eli Lilly’s tirze 6 January 2022
Mesoblast has provided new analyses from the DREAM-HF Phase III trial showing that the greatest treatment benefit from rexlemestrocel-L is in heart failure and 7 December 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.